The purpose of the present invention is to provide an antitumor drug that excels in antitumor effect and safety, and that has an excellent therapeutic effect. Provided is an antibody-drug conjugate characterized in that an antitumor compound represented by a formula and anti-TROP2 antibody are linked via a linker having a structure represented by the formula -L1-L2-LP-NH-(CH2)n1-La-(CH2)n2-C(=O)- (wherein anti-TROP2 antibody bonds with the L1 terminal and the antitumor compound bonds with the carbonyl group of the -(CH2)n2-C(=O)- moiety using the nitrogen atom of the amino group at position 1 as the bonding site).
